Your browser doesn't support javascript.
loading
Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patients.
Avivi, Irit; Shragai, Tamir; Luttwak, Efrat; Trestman, Svetlana; Cohen, Yael C.
  • Avivi I; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Shragai T; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Luttwak E; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
  • Trestman S; Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
  • Cohen YC; Department of Haematology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel.
Eur J Haematol ; 112(3): 367-370, 2024 Mar.
Article en En | MEDLINE | ID: mdl-37882735
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Mieloma Múltiple Límite: Aged / Humans Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Search on Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Anticuerpos Monoclonales Humanizados / Mieloma Múltiple Límite: Aged / Humans Idioma: En Año: 2024 Tipo del documento: Article